Shattuck Labs jumps as therapy shows promise in cancers treatment trial

Shattuck Labs

13/12/2023 12:59

** Shares of drug developer Shattuck Labs  STTK.O  more than
double to $4.4 premarket
    ** STTK reports positive initial dose-expansion data from
ongoing early stage trial testing its therapy in combination
with Azacitidine, an anti-cancer medication
    ** The trial tested company's product candidate, SL-172154,
as a monotherapy in 2 patients groups — with a type of acute
myeloid leukemia (AML) and with high-risk myelodysplastic
syndromes(HR-MDS)
    ** AML and MDS are a type of blood and bone marrow cancers
    ** In MDS and AML patient groups, respectively, company
recorded 64% and 27% of initial complete response rate or
absence of detectable cancer
    ** Company says it has amended both studies to increase the
sample size and will provide another update by mid-year 2024
    ** As of last close, stock down 8.3% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))